Home
Shilpa Biologicals

七月 2026的Shilpa Biologicals市场份额分析

An end-to-end biopharmaceutical company in India, Shilpa Biologicals delivers WHO-GMP biologics manufacturing and affordable products built to global standards.

行业: 不适用

域shilpabio.com

成立年份2007

员工201 - 500

年营收--

Shilpa Biologicals

Shilpa Biologicals（包含公司地区分支机构）

shilpabio.com

查看更多网站流量和参与度信息

Shilpa Biologicals热门域名的总访问量

了解Shilpa Biologicals市场份额和潜在市场覆盖范围。

过去 3 个月的总访问量

子公司明细

shilpabio.com1.2K

使用销售情报查看更多信息

Shilpa Biologicals热门域名的平均访问时长

分析Shilpa Biologicals参与度指标。

过去 3 个月的平均访问时长

子公司明细

shilpabio.com00:01:06

使用销售情报查看更多信息

Shilpa Biologicals热门域名的平均页面浏览量

了解Shilpa Biologicals如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。

过去 3 个月的平均页面浏览量

子公司明细

shilpabio.com2.19

使用销售情报查看更多信息

Shilpa Biologicals 排名靠前的竞争对手（按域名）

似乎没有足够的数据。

无数据可显示

Shilpa Biologicals 采用的主要技术

这些是排名前 Shilpa Biologicals 的顶级域名所使用的网站技术（按行业分列）

小部件 (6)

Twemoji

付费广告 (3)

PubMatic

内容管理系统 (3)

WordPress

转化和分析 (2)

Google Analytics

更多技术

6

查看全部

Shilpa Biologicals 的新闻与信号

借助 Similarweb 销售信号提醒，每当在目标受众之中出现新的机会或威胁时，您都会收到所识别出购买信号的每日更新。

新闻Shilpa Biologicals Private Limited hired Uday N. Harle as Chief Executive Officer on Aug 3rd '26.Shilpa Medicare has announced the appointment of Dr Uday N. Harle as the Chief Executive Officer (CEO) of Shilpa Biologicals, its wholly owned subsidiary.

新闻Shilpabio expanded facilities to India, Southern Asia, Asia on Jul 29th '26.Integrated ADC production site launched in India by Shilpa Biologics.

新闻Shilpabio is developing nivolumab biosimilar on Jul 6th '26.Dharwad (Karnataka) [India], July 6: Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world's most widely used cancer immunotherapies to widen patient access across Europe.